Evidence map›Paper›PMID 40723924›Full record

ArticleBiomolecules2025

Cullin-3 and Regulatory Biomolecules Profiling in Vitiligo: Integrated Docking, Clinical, and In Silico Insights.

Hidi A A Abdellatif, Mohamed Azab, Eman Hassan El-Sayed, Rwan M M M Halim, Ahmad J Milebary, Dhaifallah A Alenizi, Manal S Fawzy, Noha M Abd El-Fadeal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hidi A A AbdellatifMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt.ORCID 0000-0002-5346-8956
Mohamed AzabDermatology, Venereology and Andrology Department, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt.
Eman Hassan El-SayedClinical Pathology Department, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt.
Rwan M M M HalimFaculty of Medicine, Alexandria University, Alexandria 21526, Egypt.
Ahmad J MilebaryDepartment of Medical Laboratory, King Fahad Armed Forces Hospital, Jeddah 23311, Saudi Arabia.
Dhaifallah A AleniziDepartment of Medicine, Faculty of Medicine, Northern Border University, Arar 91431, Saudi Arabia.ORCID 0000-0001-8571-2231
Manal S FawzyCenter for Health Research, Northern Border University, Arar 73213, Saudi Arabia.ORCID 0000-0003-1252-8403
Noha M Abd El-FadealMedical Biochemistry and Molecular Biology Department, Faculty of Medicine, Suez Canal University, Ismailia 41522, Egypt.ORCID 0000-0003-1852-4374

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVitiligo, a chronic depigmentation disorder driven by oxidative stress and immune dysregulation, remains poorly understood mechanistically. The Keap1/NRF2/ARE pathway is critical for melanocyte protection against oxidative damage; however, the role of Cullin-3 (CUL3), a scaffold for E3 ubiquitin ligases that regulate NRF2 degradation, and its interplay with inflammatory mediators in vitiligo pathogenesis are underexplored. This study investigates CUL3, NRF2, and the associated regulatory networks in vitiligo, integrating clinical profiling and computational docking to identify therapeutic targets.

methodsA case-control study compared non-segmental vitiligo patients with age-/sex-matched controls. Lesional skin biopsies were analyzed by qRT-PCR for the expression of

resultsPatients with vitiligo exhibited significant downregulation of

conclusionsDysregulation of the CUL3/Keap1/NRF2 axis and elevated miRNA-146a levels correlate with vitiligo progression, suggesting a role for oxidative stress and immune imbalance. Vitexin's high-affinity docking to Keap1 positions it as a potential modulator of the NRF2 pathway, offering novel therapeutic avenues. This study highlights the translational potential of targeting the ubiquitin-proteasome and antioxidant pathways in the management of vitiligo.

Indexed as

Cullin ProteinsVitiligoAdultCase-Control StudiesFemaleForkhead Transcription FactorsGene Expression RegulationHumansKelch-Like ECH-Associated Protein 1MaleMicroRNAsMiddle AgedMolecular Docking SimulationNF-E2-Related Factor 2NF-kappa BTumor Necrosis Factor-alphaCUL3 protein, humanCullin ProteinsForkhead Transcription FactorsFOXP3 protein, humanKEAP1 protein, humanKelch-Like ECH-Associated Protein 1MicroRNAsMIRN146 microRNA, humanNFE2L2 protein, humanNF-E2-Related Factor 2NF-kappa BTumor Necrosis Factor-alphacullin-3 (CUL3)E3 ubiquitin ligasekeap1microRNA-146a (miR-146a)nuclear factor erythroid 2-related factor 2 (NRF2)oxidative stressvitexinvitiligovitiligo index of disease activity (VIDA) score

Identifiers

PMID40723924
PMCPMC12294106

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.